Pfizer Inc. PFE announced that its epilepsy drug, Lyrica (pregabalin), failed to meet primary endpoint in a phase III study, evaluating it as adjunctive therapy in epilepsy patients (aged 5 to 65 years) with primary generalized tonic-clonic (“PGTC”) seizures.
Data from the study showed that treatment with Lyrica was not able to achieve a statistically significant reduction in seizure frequency versus placebo in the PGTC seizure patient population.
In the United States, Lyrica is approved for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles.
Notably, the study was a post-marketing requirement by the FDA. Lyrica is not approved as adjunctive therapy for PGTC seizures in any patient population.
The phase III study evaluated two doses of Lyrica – 5 mg/kg/day and 10 mg/kg/day – over a period of 12 weeks. The safety profile of the drug was similar to observed in earlier clinical studies.
Year to date, shares of Pfizer have lost 3.9% against the industry’s 0.7% increase.
Pfizer is developing Lyrica as adjunctive therapy in a pediatric epilepsy program including six studies. The company has completed five studies in the program.
We remind investors that, in May 2018, Lyrica successfully completed a phase III study on pediatric patients with epilepsy. Top-line results from the study showed that adjunctive treatment with Lyrica 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, which was the primary efficacy endpoint. However, the treatment with Lyrica at lower dose of 7 mg did not result in statistically significant reduction in seizure frequency versus placebo.
Based on this data along with data from other studies from the pediatric epilepsy program, the drug was granted pediatric exclusivity in November 2018. Following the approval, Lyrica’s exclusivity was extended by six months to Jun 30, 2019. The drug is set to face generic competition in the U.S. markets, following the loss of exclusivity in June end.
We note that Lyrica is one of the leading brands in Pfizer’s marketed drug portfolio. In the first quarter of 2019, global sales of the drug declined 2.2% to $1.2 billion, mainly due to lower sales in the regions outside the United States, where it has lost exclusivity.
At present, several companies are developing their candidates targeting several forms of epilepsy in pediatric as well as adult patients. These include Zogenix, Inc.’s ZGNX ZX008, Insys Therapeutics, Inc.’s INSY cannabidiol oral solution and Marinus Pharmaceuticals, Inc.’s MRNS ganaxolone among others.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Insys Therapeutics, Inc. (INSY) : Free Stock Analysis Report
Zogenix, Inc. (ZGNX) : Free Stock Analysis Report
Marinus Pharmaceuticals, Inc. (MRNS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research